Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics for In vivo Efficacy under Intermittent Dosing Conditions

A mechanistically unique microtubule inhibitor in Phase III trials induces an irreversible mitotic block that contributes to its in vivo antitumor efficacy under intermittent dosing conditions.